Cyclopharm Ltd
ASX:CYC
EV/EBITDA
Enterprise Value to EBITDA
Enterprise Value to EBITDA (EV/EBITDA) ratio is a valuation multiple that compares the value of a company, debt included, to the company’s cash earnings less non-cash expenses. EBITDA can be misleading at times, especially for companies that are highly capital intensive.
Market Cap | EV/EBITDA | ||||
---|---|---|---|---|---|
AU |
C
|
Cyclopharm Ltd
ASX:CYC
|
160m AUD | -17.7 | |
US |
Abbott Laboratories
NYSE:ABT
|
182.3B USD | 19.1 | ||
US |
Intuitive Surgical Inc
NASDAQ:ISRG
|
135.1B USD | 55.8 | ||
US |
Stryker Corp
NYSE:SYK
|
123.6B USD | 23.9 | ||
IE |
Medtronic PLC
NYSE:MDT
|
111.1B USD | 14 | ||
US |
Boston Scientific Corp
NYSE:BSX
|
107B USD | 30.5 | ||
US |
Becton Dickinson and Co
NYSE:BDX
|
68.5B USD | 18.8 | ||
DE |
Siemens Healthineers AG
XETRA:SHL
|
58.8B EUR | 18.6 | ||
CN |
Shenzhen Mindray Bio-Medical Electronics Co Ltd
SZSE:300760
|
374.7B CNY | 28.3 | ||
US |
Edwards Lifesciences Corp
NYSE:EW
|
51B USD | 26.2 | ||
US |
Dexcom Inc
NASDAQ:DXCM
|
49.5B USD | 57.9 |
EV/EBITDA Forward Multiples
Forward EV/EBITDA multiple is a version of the EV/EBITDA ratio that uses forecasted EBITDA for the EV/EBITDA calculation. 1-Year, 2-Years, and 3-Years forwards use EBITDA forecasts for 1, 2, and 3 years ahead, respectively.